The present invention relates to medical devices, and more particularly, it relates to a blood volume sensor system for determining in real time the total circulating blood volume of an extracorporeal circuit associated with a patient, thereby providing continuous monitoring of blood volume changes and trending-type monitoring.
The determination of total circulating blood volume (CVB) is of substantial importance for a variety of medical situations. For example, the first and most important therapeutic goal for hemorrhagic, post operative, cardiogenic, traumatic, neurogenic for septic shock is to restore blood volume to normal levels.
A broad variety of patient conditions are associated with the abnormal blood volume levels referred to as “hypovolemia” (circulating volume too low) and “hypervolemia” (circulating volume too high). Hypovolemia occurs commonly during surgery and represents a significant cause of intestinal hypoperfusion. Hypoperfusion occurs as a response to any reduction in circulating blood volume as blood is directed away from the intestinal vascular bed in favor of vital organs. Management of circulating blood volume is essential prior to, during and following cardiopulmonary bypass procedures, inasmuch as avoiding hypovolemia improves organ perfusion and reduces morbidity and mortality. Circulating blood volume data also is important for carrying out the treatment of patients with ruptured cerebral aneurysms who often are hypovolemic. Hemorrhagic shock following traumatic injury is caused by extensive blood loss or blood loss induced trauma in the central nervous system. Failure to recognize the presence or extent of blood loss is an important factor in avoiding the loss of the patient. While hypotensive injury victims routinely receive rapid fluid resuscitation, an excessive addition of fluid into the vascular system may increase bleeding and worsen the outcome, see: Silbergleit, Schultz, et al, “A New Model of Uncontrolled Hemorrhage that Allows Correlation of Blood Pressure and Hemorrhage”, Academic Emergency Medicine, Vol. 3 No. 10, pp 917-921 (1996).
Hypovolemia is one of the principal defects contributing to cardiovascular instability and circulatory failure during septic shock. During sepsis, microcirculation often is severely impaired to exacerbate the problem of hypervolemia. Hypovolemia-induced hypotension is reported to complicate approximately 30% of all dialysis treatments. Short duration hemodialysis involving ultra filtration can cause hypovolemia unless corrective action is taken such as reducing the filtration rate or interrupting the hemodialysis process to allow for compensatory changes in the patients circulating blood volume. Acute renal failure occurs most commonly in a setting of surgery and trauma due to hypovolemia, sepsis, obstetric complications, hemolytic reaction and poisoning. A principal challenge to practitioners treating burn patients is the management of circulating blood volume in the presence of excessive plasma loss at the burn sites. Hypovolemia is a common complication of patients with burns.
However, despite the substantial importance of determining the total circulating blood volume (CBV) of a patient, making accurate CBV determinations has been an elusive undertaking. Typically, other hemodynamic parameters such as mean arterial pressure (MAP), wedge pressure (WP) or occlusion pressure, central venous pressure (CVP) and hematocrit (Hct) are used by clinicians to infer blood volume. However, such inferentially based approaches do not accurately reflect blood volume except at more extreme departures from normal levels. See in this regard: Shippey, C. R., Appel, P. L., Shoemaker, W. C., “Reliability of Clinical Monitoring to Access Blood Volume in Critically Ill Patents”, Critical Care Medicine, Vol. 12, No. 2, pp 107-112 (1984)
Conventional methods for measuring circulating blood volume depend typically upon the dilution of a dye, radioactive tracer or other analyte which, following injection is mixed into the bloodstream. Blood volume then is calculated, inter alia, from the extent of dilution and such calculation assumes that the indicator-analyte is immiscible in red blood cells.
In order to estimate total circulation blood volume (TCBV), i.e., the summation of plasma volume (PV) and red blood cell volume (RBCV), the large vessel hematocrit (LVH) also is measured so that total blood volume is obtained by the following relationships:
The most accurate method for measuring total blood volume avoids the potential error of using the large vessel hematocrit value (which is not representative of the hematocrit throughout the circulatory system) by separately measuring the plasma volume and red blood cell volume. This method is known as the Summation Method. See generally: Dagher et al, “Blood Volume Measurements: A Critical Study. Prediction of Normal Values: Controlled Measurement of Sequential Changes: Choice of a Bedside Method”, Advances In Surgery 1969; 1:69-109.
As has been reported in the literature since 1941, of the various radionuclides employed, a technique utilizing 51Cr has been considered a “gold standard” for deriving circulating blood volume values. However, this approach, as well as dye-based dilution approaches are both costly and are limited to relatively infrequent measurement. As a consequence, a continuous monitoring of blood volume changes or trending-type monitoring has not been available to practitioners. A more recent approach, utilizing 131I as a radiolabel provides for the obtaining of a plurality of blood samples over 20-35 minutes following tracer injection. Tracer dilution is combined with hematocrit to calculate blood volume. See in this regard: U.S. Pat. Nos. 5,024,231 and 5,529,189. In general, this approach has been problematic in terms of cost, limitations on the number of measurements which can be made, and the inherent procedure and physiologic limitations associated with the radionuclide.
Practitioners involved in the management of more critical hemodynamic conditions, typically turn to commonly monitored and thus more immediately available parameters such as mean arterial pressure (MAP), pulmonary catheter wedge pressure (PCWP), central venous pressure (CVP), heart rate (HR) and hematocrit (HCT) to estimate or infer a value for total circulating blood volume. Studies have shown, however, that such inference-based determinations are prone to error.
During cardiac Surgery, many complex medical devices are used to monitor and maintain patient physiology and provide life support during the procedure. Additionally, disposable medical devices mimic the function of the heart and lungs, including oxygenators and centrifugal blood pumps. A cardiopulmonary bypass (CPB) incorporates an extracorporeal circuit controlled through a heart-lung machine to circulate the patient's blood to provide physiological support during a cardiac surgery or critical life support.
Thus, there exists a need for the ability to recognize and measure of an Extracorporeal Circuit (ECV) as surrogate measure for patient circulating volume.
The present invention provides a blood volume sensor system that includes a container defining a blood volume reservoir, a volume sensor configured to monitor the blood volume reservoir and output data corresponding to a volume of blood contained in the blood volume reservoir, and a digital computing device in communication with the volume sensor and configured to receive the output data regarding the volume of blood contained in the blood volume reservoir. The volume sensor is a gravimetric sensor, an optical sensor, a contact imaging sensor, a camera sensor, or a time of flight sensor. The system additionally includes an oxygenator attached to the blood volume reservoir. The system is configured to be incorporated into a surgical pack of a heart lung machine to monitors the blood volume reservoir in real time to reflect a circulating blood volume of a patient.
The subject matter that is regarded as the invention is particularly pointed out and distinctly claimed in the claims at the conclusion of the specification. The foregoing and other objects, features, and advantages of the invention are apparent from the following detailed description taken in conjunction with the accompanying drawings in which:
The present invention has utility as a venous blood volume sensor system for determining in real time the total circulating blood volume of an ECV as a surrogate for that of a patient. An inventive system will be integral in an automated extracorporeal pump/heart lung machine) and provide real-time data as to blood volume without reliance on error prone inference-based determinations, thereby providing continuous monitoring of blood volume changes and trending-type monitoring in real-time without reliance on error prone inference-based determinations. In a specific inventive embodiment, a measurement of dynamic blood volume in an extracorporeal circuit is made while a patient is on cardiopulmonary bypass.
The present invention will now be described with reference to the following embodiments. As is apparent by these descriptions, this invention can be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. For example, features illustrated with respect to one embodiment can be incorporated into other embodiments, and features illustrated with respect to a particular embodiment may be deleted from the embodiment. In addition, numerous variations and additions to the embodiments suggested herein will be apparent to those skilled in the art in light of the instant disclosure, which do not depart from the instant invention. Hence, the following specification is intended to illustrate some particular embodiments of the invention, and not to exhaustively specify all permutations, combinations, and variations thereof.
It is to be understood that in instances where a range of values are provided that the range is intended to encompass not only the end point values of the range but also intermediate values of the range as explicitly being included within the range and varying by the last significant figure of the range. By way of example, a recited range of from 1 to 4 is intended to include 1-2, 1-3, 2-4, 3-4, and 1-4.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
Unless indicated otherwise, explicitly or by context, the following terms are used herein as set forth below.
As used in the description of the invention and the appended claims, the singular forms “a,” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
Also as used herein, “and/or” refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (“or”).
During cardiac Surgery, many complex medical devices are used to monitor and maintain patient physiology and provide life support during the procedure. Additionally, disposable medical devices mimic the function of the heart and lungs, including oxygenators and centrifugal blood pumps. These disposable systems are incorporated into a “pack” which contains various components allowing these systems to integrate with the Heart lung machine. Perfusionists are the clinicians who are responsible for the operation of these devices during an operation.
According to embodiments, the inventive blood volume sensor system is incorporated into a surgical “pack” and thereby provides perfusionists and surgeons with the ability to recognize and measure patient circulating blood volume in real-time. Accordingly, embodiments of the inventive blood volume sensor system provide vitally important information regarding patient status that allows practitioners to quickly react and avoid “hypovolemia” (circulating volume too low) and “hypervolemia” (circulating volume too high) situations that lead to negative patient outcomes. The maintenance of the patient circulating volume status affects treatment algorithms and clinical responses which would be crucial to any clinical decision support applications. It is appreciated that an inventive system is amenable to providing data to an artificial intelligence algorithm in concert with patient diagnostics to provide a learning data set to improve operation of the bypass equipment so as to inhibit blood volumetric conditions of hypovolemia and/or hypervolemia.
According to embodiments an inventive blood volume sensor system 100 is incorporated into a disposable “pack.” The system includes a venous blood reservoir 10. According to embodiments, the venous blood reservoir 10 is configured to be attached directly to left side of a patient's heart. This arrangement allows a perfusionist to drain and sequester blood from the patient, thereby allowing a surgical team to work directly on the heart. According to embodiments, the sequestered blood is shunted from the patient and stored in the reservoir 10. Simplified, this reservoir 10 reflects patient circulating volume.
As shown in
According to an embodiment as shown in
In the embodiment shown in
According to an embodiment as shown in
According to an inventive embodiment show in
The entire blood volume sensor is controlled by a microcontroller unit (MCU). By analyzing the response of the CMOS senor array, the number of blocked pixels are counted, which is linearly related on the blood level inside the reservoir. With proper calibration for the specific reservoir shape, the blood level is converted into a blood volume. With blood volumes being recorded over time, the flow rate of the net flow of blood inside the reservoir is also calculated. The results are immediately shown on a digital display mounted on the front side of the reservoir, and all data are sent to the heart-lung machine and other connected computers in real time. For each reading from the CIS device, the CMOS sensor pixels are sequentially scanned, which is controlled by a clock signal generated from the MCU. The output voltage from each CMOS sensor pixel is read by a 12-bit analog to digital conversion (ADC) on the connected MCU. The entire CMOS sensor array (comprising 5,300 CMOS sensor pixels) is scanned once in every 0.25 second, which can give 4 readings of blood volume per second. The volume readings in real time are stored in the MCU and also communicated with connected computers and the heartlung machine. The instant flow rate is calculated from two neighboring volume readings but it often contains too much fluctuations due to the noise. A more meaningful value is the average flow rate, which is calculated from volume readings sampled over a 3-second window (containing 12 readings). This average flow rate provides a stable reading to reflect the actual net flow of blood into the reservoir.
According to some inventive embodiments, the LED light source is a white LED strip (color temperature 6500 K) powered by a 24 volt DC power adapter. The intensity of light directly illuminated onto the CIS device surface was measured with a lux sensor mounted on the side of the CIS device when the reservoir was empty, and the CIS device was detached. The measured light intensity was between 3,000 lux and 5,000 lux (one lux is one lumen per square meter).
According to other inventive embodiments, the blood volume sensor relies on the optical contrast between blocked and clear CMOS sensor pixels. In the ideal scenario, the optical contrast should only come from the illumination by the LED light source. However, in practical applications, the optical contrast can be affected by the ambient light from the environment, typically in a surgical operating room. In order to minimize the interference from the ambient light, multiple layers of neutral density (ND) filter films are stacked on top of the CIS device to make a total optical density of 3.3. The ND films can effectively attenuate the ambient light into a negligible level. Since the LED light source is sufficiently strong, it can still trigger a high amplitude signal in the CMOS sensor pixel after transmitting through the ND films.
According to still other inventive embodiments, the blood volume sensor implements a CIS device to optically scan the blood inside the reservoir to find the liquid level of the blood, which is then converted into the volume. This conversion from liquid level into volume is crucial for accurate reading and it depends on the actual shapes of the specific reservoirs being used upon. For each type of reservoir, a calibration must first be done for once and the calibration coefficients will be stored in the MCU and applied for the same type of reservoir when measuring the blood volume.
According to still other inventive embodiments, the sensor is calibrated using an opaque test liquid in dark red color, which has similar optical properties with blood. This test liquid is prepared by adding food coloring agents of red, black, and crimson colors (mixed at a ratio of 2:1:2) into water. The test liquid is loaded into the reservoir by a pump to reach a specific volume determined by the volumetric marks on the original reservoir, and the response of the CMOS sensor array is analyzed to find the count of blocked pixels. Each set of volume and count of blocked pixels give one data point in the calibration curve. By changing the volume over the entire operable range (250 ml-4,000 mL), multiple data points are collected to establish a calibration curve.
To test the blood volume sensor's functions, the venous reservoir equipped with the optical blood volume sensor is used in a simulated clinical CPB procedure carried out at the Cardiovascular Perfusion SIM LAB at Comprehensive Care Services, Inc. The experiment uses a heart-lung machine (Livanova S5), a venous reservoir (Terumo CAPIOX NX19) equipped with the inventive blood volume sensor and Terumo CAPIOX FX25 Advance Oxygenator, a surgical table, and a manikin (patient simulator). The oxygenator is installed onto the reservoir which is mounted onto the post of the heart-lung machine. A traditional bypass tubing circuit is used to connect the reservoir, the oxygenator, the chest of the manikin, a centrifugal pump (Livanova REVOLUTION Blood Pump), and blood bags, into a extracorporeal circuit. Bovine blood in heparin (purchased from HemoStat Laboratories) is first loaded into the reservoir through the port on top of the arterial filter and is circulated in the extracorporeal circuit driven by the centrifugal pump. The goal for this simulated CPB procedure is to investigate how the blood volume sensor works in a clinical environment over a long period. To add blood into the reservoir or to subtract blood from the reservoir, tubings connected to the blood bags are selectively opened or closed to pump blood downward into the reservoir (to increase blood volume) or to pump blood upward into the blood bag (to decrease blood volume in the reservoir). The flow rate of blood is controlled by the centrifugal pump. Other components commonly used in clinical CPB procedures such as heat exchangers and oxygen supplies are not used in this simulation.
One key performance characteristic of the inventive blood volume sensor is the sensor's resolution, which is the smallest discernible volume change. Generally speaking, a sensor's resolution is mainly determined by its sensitivity and the signal-to-noise ratio. The present sensor's response is quite nonlinear and the sensitivity changes for different volume ranges, as can be seen from the five segments in
The non-uniform resolution can be explained from the functional mechanism of the inventive blood volume sensor. The inventive blood volume sensor optically scans the blood level and converts it into a volume reading. It can resolve the blood level with similar resolutions for different volumes. However, after converting the blood level into the volume, the resolution for larger volume is not as good as smaller volume simply because the reservoir has a larger cross-sectional area for larger volume. Compared with existing approaches of manual visual reading on the volumetric marks, the inventive blood volume sensor has improved the resolution by more than 50 times. Such a high resolution can be attributed to the small pitch size (50 μm) of the CMOS sensor pixel array. The resolution (for volume >700 mL) estimated based on the pitch size and the cross-sectional area of the reservoir is about 1 mL, which is comparable with our experimental result.
The inventive blood volume sensor has been comprehensively tested in the simulated CPB procedure.
The average flow rate indicates how quickly the venous blood volume changes over time and can provide important guidance for perfusionists to make decisions during the operation. In clinical CPB procedures, this flow rate is mainly controlled through the centrifugal pump. In some procedures, the value of flow rate may be estimated by installing two separate flow rate sensors onto the tubings connected to two main ports of the reservoir, however, such an approach is generally not accurate because it cannot capture contributions from other ports of the reservoir, such as drug injection and blood transfusion into the reservoir. In comparison, using the inventive blood volume sensor, this flow rate can be reliably measured and tracked during the entire operation.
In some inventive embodiments of the inventive blood volume sensor disclosed herein offer a powerful tool for improving clinical CPB procedures. In existing clinical CPB procedures, there are already numerous data collected in real time from multiple sensors connected with the heart-lung machine, including blood pressure, oxygen saturation, temperature, critical blood level alert, bubbles detection, and blood flow rate (through certain major tubings). However, the venous blood volume has been a missing piece of information so far. With the inventive blood volume sensor installed, the venous blood volume in the reservoir becomes a new quantity that can be promptly monitored during a CPB procedure. First of all, it can significantly improve a perfusionist's efficiency and accuracy when dealing with management of patients' blood volume. The capability of automatic recording of the blood volume over a long period can be a very beneficial feature for long-term life support. For example, an extracorporeal membrane oxygenation (ECMO) support for COVID-19 patients in critical conditions may have a median duration of 18 days. The inventive blood volume sensor can effortlessly record and track the history of venous blood volume during such a long procedure.
Furthermore, the real-time information on blood volume and average flow rate measured by certain inventive embodiments of the inventive blood volume sensor open up new applications for clinical decision support engines based on machine learning platforms. One contemplated application is the prevention of CPB-related injuries. It has been widely known that injuries may occur during or after CPB procedures, such as brain injuries, lung injuries, and kidney injuries. The fundamental reasons for such injuries still require further research. For example, brain injuries are believed to be caused by a reduced cerebral blood flow (CBF) during a CPB procedure. With the inventive blood volume sensor, the venous blood volume in the reservoir and the net flow rate are be introduced into the equations for modelling the CPB procedures to quantitatively investigate the causes of injuries. Together with all other measurable quantities, the physiology of the patient under CPB are precisely and quantitatively modelled, in order to study, and predict physiological changes during CPB procedures.
According to certain inventive embodiments as shown in
According to an inventive embodiment as shown in
According to an inventive embodiment as shown in
According to an inventive embodiment as shown in
Patent documents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These documents and publications are incorporated herein by reference to the same extent as if each individual document or publication was specifically and individually incorporated herein by reference.
The foregoing description is illustrative of particular embodiments of the invention but is not meant to be a limitation upon the practice thereof. The following claims, including all equivalents thereof, are intended to define the scope of the invention.
This application claims priority benefit of U.S. Provisional Application Ser. No. 63/287,141, filed on Dec. 8, 2021, the contents of which are hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/052204 | 12/8/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63287141 | Dec 2021 | US |